Posts tagged ‘oncology marketing’
August 29th, 2011
It is a pleasure to announce that Sally Church, PhD has been invited to be a speaker in the Distinguished Lecturer Student Seminar Series held at the Science Park campus of the University of Texas, MD Anderson Cancer Center.
The Science Park located at Smithville, just outside of Austin, TX is the location of the Victoria Harris Cockrell Cancer Research Center, where basic science research is undertaken in the Department of Molecular Carcinogenesis.
The mission of the center is “to investigate the molecular biology of cancer and to develop means for cancer prevention and detection.”
Sally’s seminar on October 5, 2011 to the graduate students in cancer research is entitled, “On Science, Blogging and Drug Development.”
We look forward to reading more about Sally’s visit and seminar on Pharma Strategy Blog.
August 2nd, 2011
Pieter Droppert recently spent a few days in Boston and Cambridge, MA. On Biotech Strategy Blog, he outlines three factors that make these two cities stand out as a biotechnology region.
Icarus Consultants is frequently in Boston/Cambridge visiting clients and undertaking business development, so do contact us if you are interested in meeting up.
Pieter has produced a short 2 minute video based on his “Letter from Boston” blog post, that you can watch below:
April 13th, 2011
That’s the question that Icarus Consultants’ oncology expert, Sally Church, Ph.D answers on Pharma Strategy Blog.
In an insightful post about “New mechanisms of resistance to MET inhibition,” Sally discusses research by Jeffrey Engelman, Jie Que and colleagues from Mass General recently published in the AACR journal, Cancer Discovery.
Gastric cancer cells have been observed to have an “oncogene addiction” to MET, so impairing or inactivating MET provides a rational for targeted therapies.
However, given that cancer calls can “escape” from an oncogene addiction through mutations or other pathways, combination therapies are often the approach to follow.
Sally proposes on Pharma Strategy Blog that “combining MET and EGFR inhibitors in gastric cancer may be a viable therapeutic strategy.”
March 25th, 2011
Mice seem to get bad PR; there’s far more people that like cats……..So in the interests of fair balance, we’d like to draw attention to the increasing importance of preclinical mouse models in cancer drug development.
Pieter Droppert on Biotech Strategy Blog discusses how innovations in translational medicine, and improved mouse models of human cancer are having a major impact on bringing new cancer drugs to market.
So, time for some good thoughts about mice (with apologies to cat lovers out there).